MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

Rucaparib

CAS No. : 283173-50-2

MCE 國際站：Rucaparib

產(chǎn)品活性：Rucaparib (AG014699) 是一種口服有效的 PARP 蛋白 (PARP-1, PARP-2 and PARP-3) 抑制劑，對 PARP-1 的 K_i 為 1.4 nM。Rucaparib 是六磷酸己糖脫氫酶 (H6PD) 抑制劑。Rucaparib 具有用于去勢抵抗性前列腺癌 (CRPC) 研究的潛力。

研究領(lǐng)域：Cell Cycle/DNA Damage  |  Epigenetics

作用靶點：PARP

In Vitro: Rucaparib (AG014699) is a possible N-demethylation metabolite of AG14644.
Rucaparib (0.1, 1, 10, 100 μM; 24 hours) is cytotoxic and has the LC₅₀ being 5?μM in Capan-1 (BRCA2 mutant) cells and only 100?nM in MX-1 (BRCA1 mutant) cells.
The radio-sensitization by Rucaparib is due to downstream inhibition of activation of NF-κB, and is independent of SSB repair inhibition. Rucaparib can target NF-κB activated by DNA damage and overcome toxicity observed with classical NF-κB inhibitors without compromising other vital inflammatory functions.
Rucaparib inhibits PARP-1 activity by 97.1% at a concentration of 1 μM in permeabilised D283Med cells.

In Vivo: Rucaparib (AG014699) and AG14584 significantly increase Temozolomide toxicity. Rucaparib (1 mg/kg) significantly increases Temozolomide-induced body weight loss. Rucaparib (0.1 mg/kg) results in a 50% increase in the temozolomide-induced tumor growth delay.
Rucaparib (10?mg/kg for i.p. or 50, 150 mg/kg for p.o.; daily for 5 days per week for 6 weeks) significantly inhibits the growth of the tumor, and there is one complete tumor regression and two persistent partial regressions.
Rucaparib (150?mg/kg; p.o.; once per week for 6 weeks or three times per week for 6 weeks) has greatest antitumor effect with three complete regressions.
Rucaparib enhances the antitumor activity of temozolomide and indicates complete and sustained tumor regression in NB1691 and SHSY5Y xenografts.

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Cell Cycle/DNA Damage Compound Library  |  Epigenetics Compound Library  |  FDA-Approved Drug Library  |  Anti-Cancer Compound Library  |  Anti-Aging Compound Library  |  Drug Repurposing Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Anti-Breast Cancer Compound Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Targeted Therapy Drug Library   |  Rare Diseases Drug Library  |  EMA-Approved Drug Library  |  FDA-Approved Anticancer Drug Library  |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Off-patent Drug Library  |  iRucaparib-AP6  |  Rucaparib monocamsylate  |  AZD-2461  |  RBN-2397  |  VEGFR/PARP-IN-1  |  Rucaparib acetate  |  Niraparib tosylate  |  Olaparib-d₈  |  G007-LK  |  Basroparib  |  Anticancer agent 64  |  UPF 1069  |  Talazoparib tosylate  |  BPA-B9  |  MSC2504877  |  Oxychlororaphine  |  PROTAC PARP1 degrader  |  5,7-Dihydroxychromone  |  PARP1-IN-5  |  OUL232  |  Stenoparib  |  PI-1840  |  PARP1-IN-11  |  3-Aminobenzamide  |  PARP1-IN-6  |  OM-153  |  BRCA1-IN-2  |  PARP-2-IN-1  |  JQAD1

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸  |  抗體  |  點擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry